SCR-LIP-000240 · Claim · machine-readable JSON →

This review identifies specific lipedema-associated variants in AKR1C genes, including the familial AKR1C1 p.Leu213Gln (L213Q) mutation segregating across three generations and reducing catalytic efficiency ~50%, the gain-of-function AKR1C2 Ser320PheTer2 mutation, AKR1C2 overexpression in 24% (5/21) of patients without coding mutations, and regulatory SNPs rs28571848 (glucocorticoid receptor site) and rs34477787 (RORα site) that increase AKR1C2/AKR1C3 expression and truncal fat mass independent of BMI.

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
low (GRADE)
Evidence
2 source(s)
Dates
2026-05-31 → 2026-06-12

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31

Evidence over time

20202026Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema — Michelini et al. (2020) · consistentFrom rare familial mutations to multifactorial disease: aldo-keto reductase 1C enzymes as a central biological pathway in lipedema — Vainberg et al. (2026) · consistent

Evidence (2)

Context (PECO)

Populationwomen with lipedema
Conditionlipedema
ExposureAKR1C1/AKR1C2/AKR1C3 gene variants and overexpression
Outcomelipedema association, fat distribution, catalytic efficiency
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log